WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: 2-CHF, hypotensive effect of metoprolol Risk rating C, B-type Natriuretic Peptide (BNP) released from left ventricle inhibit remodeling of progressive worsening of LV function, patient medications furosemide (diuretic), Entresto Class ARNI (angiotensin-II blocker and neprilysin inhibitor), vasopressin (ADH) V2 kidneys (fluid reabsorbtion), Blood Vessels (constriction) increase systemic vascular resistance, Neprilysin Inhibitor Medication Therapy Combination Therapy, ranitidine (histamine H2 antagonist) why not? cost restraints, patient medications Entresto, Angiotensin II by ACE Activation of Angiotensin II type 1 (AT1) Receptors Vascular smooth muscle, afterload Resulting in Remodeling and Progressive Worsening of LV Function, an ARNI (recommended to further reduce morbidity and mortality) Reccommendation Patient should purchase Entresto with free trial coupon from manufacturer, abdomen and tenderness, CHF Class III pathophysiology myocardial injury, patient conditions Insulin-dependent diabetes, Angiotensin II by ACE Activation of Angiotensin II type 1 (AT1) Receptors heart contractility increased, CHF Class III symptoms swelling, Neprilysin Inhibitor Medication Therapy Monotherapy, Monotherapy ineffective did not produce clinically meaningful reductions in blood pressure, B-type Natriuretic Peptide (BNP) released from left ventricle inhibit peripheral vasoconstriction